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Introduction {#s0001}
============

Primary cilia are microtubule-based compartments found on almost every eukaryotic cell. They function as the cell\'s antenna receiving and transducing signals from the environment and consist in a simplified form of the basal body (BB), the axoneme and the transition zone (TZ). While the BB anchors the cilium in the cell, and the axoneme is a microtubule-based scaffold for the ciliary projection out of the cell\'s surface, the TZ is in control of ciliary protein import and export. Defects in ciliary protein composition have been linked to severe human pathologies summarized as ciliopathies with symptoms ranging from mental retardation to cystic kidneys and skeletal malformations \[[@cit0001]\]. The wide range of symptoms can be traced back to the dysregulation of cilia-mediated signaling pathways such as the SHH (sonic hedgehog) pathway. These pathways control cellular processes, e.g. proliferation, cell migration, differentiation or apoptosis \[[@cit0005]\].

In 2013, 2 studies revealed an association between primary cilia and autophagy. Tang et al. showed that clearance of OFD1/orofaciodigital syndrome protein 1 (OFD1, centriole and centriolar satellite protein), a protein located at the BB, is dependent on autophagy \[[@cit0006]\], while Pampliega et al. demonstrated a functional interaction between cilia and autophagy in which cilia-mediated SHH signaling is able to promote autophagic activity \[[@cit0007]\]. Furthermore, autophagy is regulated in a negative manner by the MTOR (mechanistic target of rapamycin \[serine/threonine kinase\]) signaling pathway. This highly conserved pathway is characterized by the serine-threonine kinase MTOR, which forms 2 different complexes, MTORC1/MTOR complex 1 and MTORC2/MTOR complex 2, depending upon its interaction partners. Whereas MTORC1 is the regulating complex for autophagy and protein synthesis, it is suggested that MTORC2 is involved in microtubule organization \[[@cit0008],[@cit0009]\]. The activation of the MTOR protein in complex 1 is realized by its phosphorylation at Ser2448 \[[@cit0010],[@cit0011]\]. MTORC1 activity can be influenced by several factors: The known main regulator of the MTORC1 is a heterodimeric protein complex consisting of TSC1 (tuberous sclerosis 1) and TSC2. Interaction of these proteins leads to a strong suppression of MTORC1 activity \[[@cit0012]\]. Another factor that modulates MTORC1 activity is AKT1 (AKT serine/threonine kinase 1). As with MTORC1, AKT1 is a well-known signaling node in vertebrate signal transduction \[[@cit0013]\]. AKT1 is activated by phosphorylation at Thr308 and subsequently at Ser473 \[[@cit0014]\]. Activated AKT1 modulates MTORC1 signaling in different ways: On the one hand, several studies indicate that AKT1 is able to phosphorylate TSC2 and thereby activate the TSC1/2 complex \[[@cit0018]\]. On the other hand, studies reveal that MTORC1 can be phosphorylated directly at the Ser2448 residue via AKT1 \[[@cit0021]\]. In its activated form, MTORC1 inhibits autophagy via preventing the formation of autophagosomes, while it increases protein synthesis \[[@cit0022]\].

*Rpgrip1l/Ftm/Mks5/Nphp8* (Rpgrip1-like) encodes a protein that is localized at the ciliary transition zone \[[@cit0028]\] and *Rpgrip1l*-deficient mouse embryos die, at the latest, around birth displaying a severe ciliopathy phenotype \[[@cit0029],[@cit0030]\]. Moreover, mutations in *RPGRIP1L* are found in patients suffering from deadly ciliopathies like the Meckel-Gruber or Joubert Syndrome \[[@cit0030]\]. Recently, we described that RPGRIP1L regulates proteasomal activity at primary cilia and thereby controls cilia-mediated SHH signaling \[[@cit0028]\].

In our current study, we report that RPGRIP1L additionally controls autophagy and that RPGRIP1L seems to regulate both predominant protein degradation processes of eukaryotes independently from each other. We demonstrate that RPGRIP1L positively governs autophagic activity via regulating autophagy initiation by controlling MTOR signaling. Moreover, we suggest that RPGRIP1L might govern later steps of autophagy by a yet unknown mechanism. Our data highlight impaired autophagy as one factor that contributes to or even causes deadly ciliopathies and suggest autophagy as a potential therapeutic target for the treatment of ciliopathies. Given that RPGRIP1L regulates both autophagy and proteasomal activity at the ciliary base, a combined treatment of ciliopathies caused by mutations in *RPGRIP1L* should be taken into consideration.

Results {#s0002}
=======

Recently, we showed that *Rpgrip1l*-deficient mouse embryos suffer from a decreased proteasomal activity specifically at the base of primary cilia leading to a dysregulation in cellular signaling pathways such as the canonical WNT (wingless-type MMTV integration site family) or SHH pathway \[[@cit0028]\]. Although treatment with the well-known proteasome activator sulforaphane (SFN) rescues proteasomal activity at the base of *Rpgrip1l*-negative cilia, ciliary length is not restored indicating that at least one other factor is responsible for the ciliary dysfunction caused by RPGRIP1L deficiency \[[@cit0028]\]. It is known that autophagy is able to compensate a reduced proteasomal activity \[[@cit0033],[@cit0034]\]. However, the strong mutant phenotype of *Rpgrip1l*-negative mouse embryos suggests that there is no compensation. Consequently, we analyzed autophagic activity in wild-type and *Rpgrip1l*-deficient mouse embryonic fibroblasts (MEFs) via measuring the quantities of autophagosomes.

MEFs were serum starved for 24 h to induce ciliogenesis and autophagy, and then immunostained for ATG5 (autophagy-related 5) and MAP1LC3B (microtubule-associated protein 1 light chain 3 beta), which represent well-known marker proteins for the quantification of autophagosomes; we determined the amount of autophagosomes by quantifying the ATG5 and MAP1LC3B-positive signals \[[@cit0035]\]. Both the number of autophagosomes and the autophagosomal ratio (autophagosomal area per cell area) were significantly decreased in *Rpgrip1l*-negative MEFs ([Figure 1](#f0001){ref-type="fig"}A-Aii and [Figure 1](#f0001){ref-type="fig"}B-Bii). By performing western blot analyses with protein lysates obtained from MEFs after 24-h serum starvation, we demonstrated that RPGRIP1L deficiency results in a decreased amount of MAP1LC3B-II ([Figure 1C](#f0001){ref-type="fig"}), which is the form of MAP1LC3B that is recruited to phagophore (the autophagosome precursor) membranes. Because MAP1LC3B-II is not only closely correlated with the number of autophagosomes but is also finally degraded in the autolysosomal lumen, we performed an autophagic flux assay with MEFs which were serum starved for 24 h ([Figure 1D](#f0001){ref-type="fig"}) \[[@cit0036],[@cit0037]\]. In this assay, we inhibited both fusion of autophagosomes with lysosomes and lysosomal protein degradation by using chloroquine (CQ) and measured the amount of MAP1LC3B-II. After incubation in CQ for 6 h, MAP1LC3B-II accumulated in wild-type MEFs but not in *rpgrip1l*^−/−^ MEFs ([Figure 1D](#f0001){ref-type="fig"}) implicating a reduced autophagic flux in the absence of RPGRIP1L. Figure 1.RPGRIP1L deficiency results in a decreased autophagic activity. (A to Aii) Immunofluorescence staining of ATG5 in wild-type and *Rpgrip1l*-negative MEFs. Cells were visualized by marking F-ACT (Phalloidin 488, green), and cells as well as cell nuclei were visualized by marking TUBG (blue). ATG5-positive autophagosomes were stained in red (n = 3). Scale bar: 5 µm. Either the number of ATG5-positive vesicles (Ai) or the ratio between the area of ATG5-positive vesicles and the total cell area (Aii) were quantified. The amount and the area of ATG5-positive vesicles per cell are significantly reduced. (B to Bii) Immunofluorescence staining on MEFs isolated from wild-type and *Rpgrip1l*-negative mouse embryos. Cells were visualized by marking F-ACT (Phalloidin 488, green) and cells as well as cell nuclei were visualized by marking TUBG (blue). Autophagosomes were stained by visualizing MAP1LC3B (red) (n = 4). Scale bar: 5 µm. Either the number of MAP1LC3B-positive vesicles (Bi) or the ratio between the area of MAP1LC3B-positive vesicles and the total cell area (Bii) were quantified. The amount and the area of MAP1LC3B-positive vesicles per cell are significantly reduced. (C) Western blot analysis of MAP1LC3B-II in MEFs (n = 3). The amount of MAP1LC3B-II is reduced in *Rpgrip1l*-negative MEFs. (D) Autophagic flux assay performed on MEFs serum starved for 24 h including 6-h CQ treatment (n = 4). Inhibition of lysosomal fusion via CQ-treatment leads to an accumulation of MAP1LC3B-II in wild-type but not in *Rpgrip1l*-deficient MEFs. (E) Autophagic flux assay performed on MEFs serum starved and CQ treated for 6 h (n = 8). Inhibition of lysosomal fusion via CQ treatment leads to an accumulation of MAP1LC3B-II in wild-type but not in *Rpgrip1l*-deficient MEFs. (F) Immunofluorescence-based measurement of OFD1 as an autophagic substrate at the base of wild-type and *Rpgrip1l*-deficient MEFs. The axoneme was stained with Ac-TUBA (green), the basal body with TUBG (blue) and OFD1 was stained in red (n = 3). Scale bar: 2.5 µm in the overview and 1 µm in the insets. The amount of OFD1 is significantly increased at the base of *rpgrip1l*^−/−^ MEFs. (G) Immunofluorescence-based quantification of the BBS4 amount at the base of wild-type and *rpgrip1l*^−/−^ MEFs (n = 6). The axoneme was marked with Ac-TUBA (green), the basal body with TUBG (blue), and BBS4 was stained in red. Scale bar: 1 µm. The amount of BBS4 found at the base of *Rpgrip1l*-deficient cilia is significantly decreased. (A to G) Asterisks indicate statistically significant differences. p.d.u., procedure defined unit.

To evaluate whether the effect of RPGRIP1L on autophagy is cilia-dependent, we performed another autophagic flux assay with MEFs that were serum starved for only 6 h. After serum starvation for 6 h, 10.4% of the wild-type MEFs possessed cilia (Figure S1A). After serum starvation for 24 h, 72.1% of the wild-type MEFs displayed cilia. None of the *Rpgrip1l*-deficient MEFs showed cilia after serum starvation for 6 h, while 15.9% of the *rpgrip1l*^−/−^ MEFs carried cilia after serum starvation for 24 h (Figure S1A). Similar to the autophagic flux assay performed with MEFs that underwent serum starvation for 24 h, the autophagic flux was reduced in MEFs that were serum starved for 6 h ([Figure 1E](#f0001){ref-type="fig"}). Consequently, the presence or absence of cilia does not seem to be the decisive event that leads to the reduced autophagic flux in *rpgrip1l*^−/−^ MEFs. It might be rather the difference in the number of cilia between wild-type and *Rpgrip1l*-deficient MEFs under both conditions (6 h and 24 h serum starvation), respectively.

Remarkably, the MAP1LC3B-II amount of *Rpgrip1l*-negative MEFs in comparison to that of wild-type MEFs without CQ treatment was different after serum starvation for 6 h compared with that for 24 h. After serum starvation for 24 h, the amount of MAP1LC3B-II was decreased in *rpgrip1l*^−/−^ MEFs ([Figure 1B-D](#f0001){ref-type="fig"}). After serum starvation for 6 h, the amount was increased in *rpgrip1l*^−/−^ MEFs ([Figure 1E](#f0001){ref-type="fig"} and Figure S1B). Because the autophagic flux was reduced in the absence of RPGRIP1L after serum starvation for 6 h and 24 h, this result was surprising. In order to validate this finding, we performed immunofluorescence studies in MEFs that were serum starved for 6 h by immunostaining of MAP1LC3B-II. In these MEFs, the autophagosomal ratio was increased (Figure S1C) verifying the data of the western blot studies. Interestingly, the MAP1LC3B signals were mainly localized in the nuclei of wild-type and *Rpgrip1l*-deficient MEFs that were serum starved for 6 h (Figure S1C), whereas these signals were predominantly found in the cytoplasm in wild-type and *Rpgrip1l*-negative MEFs which were exposed to serum starvation for 24 h ([Figure 1B](#f0001){ref-type="fig"}).

To assess what kind of MAP1LC3B situation occurs in vivo, we used cryosections of wild-type and *Rpgrip1l*-deficient limb buds as a well-established in vivo model for analyzing functional mechanisms in terms of cilia research\[[@cit0028],[@cit0038]\]. The quantification of MAP1LC3B-positive signals in *Rpgrip1l*-negative limb bud cells revealed a significant reduction of autophagosomes by about half (Figure S2A-Aii) confirming the cell culture data obtained from experiments with MEFs that underwent serum starvation for 24 h. Because the situation in which a high number of cilia is present seems to be more natural than a situation in which only a few cilia are existing, we used MEFs that were serum starved for 24 h in all following experiments.

Previously, it was reported that the ciliary protein OFD1 (OFD1, centriole and centriolar satellite protein) is cleared from the basal body via autophagy making it an autophagic substrate \[[@cit0006]\]. To test whether autophagic activity is decreased in the abscence of RPGRIP1L, we quantified fluorescence intensities of OFD1 directly at the base of primary cilia in wild-type and *Rpgrip1l*-deficient MEFs as well as limb bud cells. OFD1 accumulated at the ciliary base of cells that lack RPGRIP1L ([Figure 1F](#f0001){ref-type="fig"} and S2B). Another protein influenced by autophagy is BBS4 (Bardet-Biedl syndrome 4). The ciliary recruitment of BBS4 is dependent on autophagy \[[@cit0006]\]. In *rpgrip1l^−/−^* MEFs and limb bud cells, the amount of BBS4 at the ciliary base is reduced, thereby arguing for a decreased autophagy-mediated ciliary localization of this protein ([Figure 1G](#f0001){ref-type="fig"} and Figure S2C). All these data demonstrate that RPGRIP1L deficiency impairs autophagy. Combining these data with those from our previous study, we conclude that RPGRIP1L positively controls proteasomal activity at the ciliary base and autophagic activity \[[@cit0028]\].

Former studies revealed that autophagy is negatively regulated by MTORC1 signaling \[[@cit0042]\]. Remarkably, cells that lack the ciliary protein IFT88 (intraflagellar transport 88) and do not form cilia have a higher activity of MTORC1 and a higher protein synthesis \[[@cit0043]\]. In search of how RPGRIP1L controls autophagy, we analyzed the amount of phosphorylated and thereby activated MTORC1. Indicative for its activity is the phosphorylation at Ser2448\[[@cit0010],[@cit0011]\]. The amount of phospho-(Ser2448)-MTOR was increased in *Rpgrip1l-*deficient MEFs ([Figure 2A](#f0002){ref-type="fig"}) indicating that RPGRIP1L deficiency affects MTOR activation and thereby MTOR signaling. In this context, we investigated other downstream effects of MTORC1 signaling. In addition to the negative regulation of autophagy, MTORC1 stimulates protein synthesis \[[@cit0044]\]. In this context, a former report revealed that autophagy regulates the volume of kidney cells \[[@cit0043]\]. Previously, it was shown that the size of a cell correlates with its protein synthesis. The bigger the cell, the more proteins are produced in this cell \[[@cit0048]\]. In *Rpgrip1l-*deficient limb buds, cells are larger than those of their wild-type littermates ([Figure 2B](#f0002){ref-type="fig"}). Based on these cell size quantifications, we conclude that protein synthesis is increased by RPGRIP1L deficiency reflecting the situation of elevated MTORC1 signaling. Figure 2.RPGRIP1L deficiency leads to upregulated MTORC1 signaling. (A) Western blot studies for phospho-(Ser2448)-MTOR in MEFs (n = 3). The amount of phospho-(Ser2448)-MTOR is increased in total cell lysates of *Rpgrip1l*-negative MEFs. Nonphosphorylated MTOR was used for normalization, while ACT served as a loading control. (B) Immunofluorescence-based measurement of cell size of wild-type and *rpgrip1l*^−/−^ limb bud cells. The cells were visualized with TRITC-Phalloidin marking F-ACT to monitor the cell size (in both cases: n = 4). For better visualization the same cells were depicted without and with cell size indication (yellow dotted lines). The cell size of *rpgrip1l*^−/−^ limb bud cells is significantly increased. (C) Semiquantitative PCR analysis for *Hif1a*, a target of MTORC1 signaling (n = 3). The expression of *Hif1a* is almost doubled in *Rpgrip1l*-deficient MEFs. For better visualization of the DNA bands, the gel electrophoresis photo was color inverted. (D) Immunofluorescence-based measurement of the OFD1 amount at the base of wild-type and *Rpgrip1l*-negative MEFs treated with either DMSO (control) or rapamycin. The axoneme was stained with Ac-TUBA (green), the basal body with TUBG (blue), and OFD1 was stained in red (n = 4). Scale bar: 1 µm. Rapamycin treatment resulted in a significant reduction of the OFD1 amount at the ciliary base in both genotypes. (A to D) Asterisks indicate statistically significant differences. (D) The most important significant differences are written in bold.

Another downstream target of MTORC1 signaling is *HIF1A* (hypoxia inducible factor 1 alpha subunit), which is positively regulated by MTORC1 \[[@cit0049]\]. In *Rpgrip1l*-negative MEFs, the expression of *Hif1a* was elevated ([Figure 2C](#f0002){ref-type="fig"}). Taken together, these data let us assume that RPGRIP1L regulates autophagic activity via MTORC1. To demonstrate whether RPGRIP1L controls autophagy indeed by regulating MTOR signaling, we used rapamycin. The macrolide rapamycin is a well-known inhibitor of MTORC1 \[[@cit0050]\]. It was shown that rapamycin is specifically suppressing MTORC1, while MTORC2 is relatively unaffected\[[@cit0008],[@cit0009]\]. Treatment of *Rpgrip1l*-negative MEFs with rapamycin was performed to test if a downregulation of MTOR signaling results in an elevation of autophagic activity. This treatment resulted in a reduction of the OFD1 amount at the ciliary base in *Rpgrip1l*-deficient MEFs ([Figure 2D](#f0002){ref-type="fig"}) implying a rescue of autophagic activity caused by rapamycin treatment. Consequently, RPGRIP1L regulates autophagy by governing MTOR signaling.

To examine how RPGRIP1L affects MTORC1, we focused on the events that lie upstream of MTORC1 action. To analyze a possible effect of RPGRIP1L on the TSC1/2 complex, we quantified the amount of TSC1 and phosphorylated TSC2. The amount of both TSC proteins was unaltered in *Rpgrip1l*-deficient MEFs ([Figure 3A](#f0003){ref-type="fig"} and B). Moreover, we investigated the amount of phospho-(Ser473)-AKT1 and found it to be elevated in whole cell lysates upon *RPGRIP1L* deficiency ([Figure 3C](#f0003){ref-type="fig"}). Former studies reported the presence of AKT1 and activated (phosphorylated at Ser473) AKT1 at cilia. In 3T3-L1 preadipocytes, AKT1 is present in the entire cilium \[[@cit0057]\]. After phosphorylation of AKT1 at Ser473, the localization changes and phospho-(Ser473)-AKT1 is detected at the basal body\[[@cit0057],[@cit0058]\]. In immortalized fibroblasts (NIH3T3 cells), phospho-(Ser473)-AKT1 localizes at the ciliary base \[[@cit0059]\]. Because we obtained all in vitro data of this study in MEFs, the localization of phospho-(Ser473)-AKT1 was checked in these cells. By using super-resolution microscopy, we detected phospho-(Ser473)-AKT1 spread over the entire cilia of wild-type MEFs ([Figure 3D](#f0003){ref-type="fig"}). Next, we quantified the amount of phospho-(Ser473)-AKT1 at cilia of *Rpgrip1l*-negative MEFs. In the absence of RPGRIP1L, phospho-(Ser473)-AKT1 was significantly elevated ([Figure 3E](#f0003){ref-type="fig"}). Interestingly, we found the active form of MTOR, phospho-(Ser2448)-MTOR, at the base of primary cilia in wild-type MEFs ([Figure 3F](#f0003){ref-type="fig"}) making it likely that phospho-(Ser473)-AKT1 phosphorylates MTOR at primary cilia. In line with this assumption, RPGRIP1L deficiency resulted in an increased amount of phospho-(Ser2448)-MTOR at the ciliary base ([Figure 3G](#f0003){ref-type="fig"}). In summary, we propose that RPGRIP1L regulates autophagic activity by governing the amount of phospho-(Ser473)-AKT1 at the primary cilium. Figure 3.RPGRIP1L deficiency regulates autophagy not by governing SHH signaling but by controlling AKT1 signaling. (A) Western blot studies for TSC1 (n = 3). The amount of TSC1 is unchanged in *Rpgrip1l*-deficient MEFs compared to their wild-type littermates. ACT served as a loading control. (B) Western blot studies for phospho-(Ser939)-TSC2. Nonphosphorylated TSC2 was used for normalization, while ACT served as a loading control (n = 3). The amount of phospho-(Ser939)-TSC2 is unaltered comparing wild-type and *Rpgrip1l*-deficient MEFs. Non-phosphorylated TSC2 was used for normalization, and ACT serves as a loading control. (C) Western blot studies for phospho-(Ser473)-AKT1. Non-phosphorylated AKT1 was used for normalization, while ACT served as a loading control (n = 3). The amount of phospho-(Ser473)-AKT1 is significantly elevated in *rpgrip1l*^−/−^ MEFs. (D) Immunofluorescence studies in wild-type MEFs. Pictures were obtained using 3D-SIM. The ciliary axoneme was stained with Ac-TUBA (green), the basal body with TUBG (blue). Phospho-(Ser473)-AKT1 was stained in red and is located at the primary cilium of wild-type MEFs. Scale bar: 1 µm. (E) Immunofluorescence-based quantification of phospho-(Ser473)-AKT1 at wild-type and *Rpgrip1l*-deficient cilia in MEFs. The axoneme was stained with Ac-TUBA (green), the basal body with TUBG (blue) and phospho-(Ser473)-AKT1 was stained in red (n = 3). Scale bar: 1 µm. The amount of phospho-(Ser473)-AKT1 is significantly increased at the cilia of *rpgrip1l*^−/−^ MEFs. (F) Immunofluorescence studies in wild-type MEFs. Pictures were obtained using 3D-SIM. The ciliary axoneme was stained with Ac-TUBA (green), the basal body with TUBG (blue). Phospho-(Ser2448)-MTOR was stained in red and is located at the base of primary cilia of wild-type MEFs. Scale bar: 1 µm. (G) Immunofluorescence-based measurement of phospho-(Ser2448)-MTOR at wild-type and *Rpgrip1l*-deficient cilia in MEFs. The axoneme was stained with Ac-TUBA (green), the basal body with TUBG (blue) and phospho-(Ser2448)-MTOR was stained in red (n = 3). Scale bar: 1 µm. The amount of phospho-(Ser2448)-MTOR is significantly increased at the base of *rpgrip1l*^−/−^ MEFs. (H) Quantitative real-time reverse transcriptase-PCR studies for *Ptch1* in SAG-treated *Rpgrip1l*-deficient MEFs compared with SAG-treated wild-type MEFs (n = 3). The relative induction of *Ptch1* in *Rpgrip1l*-deficient MEFs is reduced about 60%. (I) Immunofluorescence studies on wild-type and *Rpgrip1l*-deficient MEFs after GLI1 overexpression. The cells were visualized by marking F-ACT (Phalloidin 405, blue), ATG5 was stained in red (n = 3). In the single channel images the F-ACT staining is shown in white to provide a high contrast between the black background and the outline of the cells which are marked by the F-ACT staining. Scale bar: 5 µm. The amount of ATG5 is increased after transfection with a plasmid expressing GLI1 in wild-type MEFs, while the amount of ATG5 remains unaltered after GLI1 overexpression in *Rpgrip1l*-deficient MEFs. (J) BBS4 staining of wild-type and *Rpgrip1l*-deficient MEFs after transfection with a plasmid expressing GLI1. Cilia were marked with Ac-TUBA (red), BBS4 was stained in blue (n = 3). Scale bar: 1 µm. The amount of BBS4 is increased after GLI1 overexpression in wild-type MEFs, while the amount of BBS4 remains unaltered after GLI1 transfection in *Rpgrip1l*-deficient MEFs. (C to J) Asterisks indicate statistically significant differences. (I and J) The most important significant differences are written in bold.

In a previous study, Pampliega et al. monitored autophagic flux in *ift20^−/−^/intraflagellar transport 20^−/−^* and *ift88^−/−^* MEFs and found it to be decreased \[[@cit0007]\]. Interestingly, this decreased autophagic flux could not be elevated via application of rapamycin. The authors showed that deficiency of the ciliary proteins IFT20 and IFT88 results in an abnormal SHH signaling, which in turn leads to a dysregulation in autophagy and can be compensated via overexpression of *GLI1* \[[@cit0007]\]. In our case, rapamycin is able to compensate for the decreased autophagic activity in *Rpgrip1l*-negative MEFs ([Figure 2D](#f0002){ref-type="fig"}). In former reports, we demonstrated a downregulation of SHH signaling in embryonic limbs \[[@cit0029]\], neural tubes \[[@cit0029]\] and embryonic hearts \[[@cit0060]\]. In our current study, we revealed a decreased expression of the SHH target gene *Ptch1* (*patched 1*) in SAG (Smoothened agonist)-treated *rpgrip1l*^−/−^ MEFs ([Figure 3H](#f0003){ref-type="fig"}). Consequently, the question arises whether RPGRIP1L regulates autophagic activity exclusively via governing MTOR signaling or whether this regulation is additionally realized by controlling SHH signaling. To address this issue, we overexpressed GLI1 (Figure S2D) and quantified the number of autophagosomes by marking ATG5 in whole cells as well as the amount of BBS4 at the ciliary base of wild-type and *rpgrip1l*^−/−^ MEFs. The amount of both ATG5 and BBS4 was significantly increased in transfected wild-type MEFs ([Figure 3I](#f0003){ref-type="fig"} and J) confirming the finding of Pampliega and colleagues \[[@cit0007]\]. However, their amount was unaltered in GLI1-overexpressing *Rpgrip1l*-negative MEFs ([Figure 3I](#f0003){ref-type="fig"} and [J](#f0003){ref-type="fig"}) demonstrating that RPGRIP1L regulates autophagy independently of SHH signaling.

Previously, we reported that RPGRIP1L affects SHH signaling at the level of GLI3 processing by regulating proteasomal activity at the ciliary base. In *rpgrip1l^−/−^* MEFs, the activity of the proteasome at the ciliary base is decreased \[[@cit0028]\]. Consequently, the restoration of this proteasomal activity in the absence of RPGRIP1L should alter autophagic activity if RPGRIP1L regulates autophagy via SHH signaling. We treated *Rpgrip1l*-negative MEFs with SFN and with 18α-glycyrrhetinic acid (18α-GA), 2 well-known activators of proteasomal activity\[[@cit0061],[@cit0062]\]. Previously, we showed that the treatment with SFN decreases the ciliary amount of proteasomal substrates in wild-type MEFs and rescues their amount at the ciliary base of *Rpgrip1l*-deficient MEFs \[[@cit0028]\]. Quantification of BBS4 and OFD1 at the ciliary base after incubation of wild-type and *Rpgrip1l*-deficient MEFs in SFN showed no difference in the amount of both proteins between the control MEFs and the littermates (Figure S3A and S3B). In wild-type and *rpgrip1l*^−/−^ MEFs, the proteolytic processing was clearly increased by treatment with 18α-GA (Figure S4A), demonstrating that the incubation of MEFs in 18α-GA increased proteasomal activity at the ciliary base. However, the amount of the autophagy-associated proteins OFD1 and BBS4 was unchanged at the base of cilia in wild-type and *rpgrip1l*^−/−^ MEFs after treatment with 18α-GA (Figure S4B and C). On the basis of these results, we suggest that RPGRIP1L controls autophagy neither via governing SHH signaling nor via regulating proteasomal activity at the primary cilium.

Interestingly, it was shown previously that BBS4 is able to positively regulate proteasomal activity \[[@cit0063]\]. Because the autophagy-dependent ciliary localization of BBS4 is impaired in the absence of RPGRIP1L, the question arises whether a rescue of autophagic activity would restore proteasomal activity at the ciliary base. To address this question, we used 4-(4-\[{4′-chloro-2-biphenyl}methyl\]-1-piperazinyl)-N-\[{4-(\[{2R}-4-{dimethylamino}-1-{phenylsulfanyl}-2-butanyl\]amino)-3-nitrophenyl} sulfonyl\]benzamide (ABT-737), another known activator of autophagy aside from rapamycin \[[@cit0064]\]. Because activation of autophagy neither affects GLI3 processing in the wild-type nor in the *rpgrip1l^−/−^* status (Figure S5A), we propose that RPGRIP1L regulates autophagy and proteasomal activity at the primary cilium independently of each other. To further analyze if the repression of autophagic activity affects GLI3 processing, we used 3-methyladenine (3-MA), a known inhibitor of autophagy \[[@cit0065]\]. Treatment of wild-type as well as *Rpgrip1l*-negative MEFs with 3-MA did not alter the processing of GLI3 (Figure S5B).

Phospho-(Ser33/37/Thr41)-CTNNB1/β-catenin 1 represents another substrate that is specifically degraded by the proteasome at the ciliary base\[[@cit0028],[@cit0066]\]. After treatment with the autophagy activator rapamycin, the amount of phospho-(Ser33/37/Thr41)-CTNNB1 at the ciliary base was unaltered in wild-type and *Rpgrip1l*-negative MEFs (Figure S5C) revealing that phospho-(Ser33/37/Thr41)-CTNNB1 is not degraded by autophagy and is not affected or even rescued by the restored autophagic activity in rapamycin-treated *rpgrip1l*^−/−^ MEFs. To sum up, these data indicate that the known dysregulation of SHH signaling in *Rpgrip1l*-deficient individuals is not responsible for the diminished autophagic activity, and that RPGRIP1L regulates autophagy independently of proteasomal activity at the ciliary base.

Previously, we showed that treatment of *Rpgrip1l*-negative MEFs with SFN restores proteasomal activity at the ciliary base but not cilia length indicating that additional factors besides the reduced proteasomal activity cause the numerous defects of *Rpgrip1l*-deficient embryos \[[@cit0028]\]. Because treatment with rapamycin did not only decrease the OFD1 amount but also restored ciliary length in *rpgrip1l^−/−^* MEFs ([Figure 2D](#f0002){ref-type="fig"} and [Figure 4A](#f0004){ref-type="fig"}), the reduced autophagic activity might be another factor that leads to the defects observed in *rpgrip1l^−/−^* mouse embryos. Protein synthesis and autophagy are both mediated by MTORC1 \[[@cit0022]\]. Previously, it was reported that MTOR modulates ciliary length via controlling protein synthesis \[[@cit0067]\]. Thus, the question arises whether ciliary length in *Rpgrip1l*-deficient mice is altered due to rapamycin-induced changes in protein synthesis or due to the altered autophagy. To analyze this, we treated wild-type and *rpgrip1l*^−/−^ MEFs with either the autophagy inhibitor 3-MA, acting independently of MTOR, or with the autophagy activator ABT-737, which was not shown to be associated with protein synthesis until now\[[@cit0064],[@cit0068]\]. Treatment of wild-type MEFs with 3-MA resulted in an increase of ciliary length demonstrating that a reduction of autophagic activity increases cilia length independently of MTOR ([Figure 4B](#f0004){ref-type="fig"}). However, treatment of *Rpgrip1l*-negative MEFs with 3-MA did not alter cilia length ([Figure 4B](#f0004){ref-type="fig"}). Incubation in ABT-737 led to a decrease of cilia length in wild-type and *rpgrip1l*^−/−^ MEFs, respectively ([Figure 4C](#f0004){ref-type="fig"}). Together these data indicate that although the reduction of autophagy in the absence of RPGRIP1L is based on an increased amount of active MTORC1, the changes in ciliary length of *rpgrip1l*^−/−^ mouse embryos are not caused by the increased protein synthesis but by the reduced autophagic activity. Figure 4.Pharmacological treatments rescue autophagic activity and ciliary length in the absence of RPGRIP1L. (A to C) Immunofluorescence-based cilia length quantifications. (A) Measurement of ciliary length after rapamycin treatment. The ciliary length in wild-type and *Rpgrip1l*-deficient MEFs is decreased after application of rapamycin (n = 3). (B) Application of the autophagy inhibitor 3-MA lengthens cilia in wild-type MEFs, but not *Rpgrip1l*-deficient MEFs. The ciliary axoneme is marked by Ac-TUBA (green), the basal body by TUBG (blue) (n = 4 for wild-type; n = 5 for *rpgrip1l^−/−^* MEFs). Scale bar: 1 µm. (C) Application of the autophagy activator ABT-737 decreases ciliary length in wild-type and *Rpgrip1l*-deficient MEFs. The ciliary axoneme is stained with Ac-TUBA (green), the basal body with TUBG (blue) (n = 4 for wild-type; n = 5 for *Rpgrip1l^−/−^* MEFs). Scale bar: 1 µm. Asterisks indicate statistically significant differences. The most important significant differences are written in bold. (A and C) Cells were treated with DMSO as a vehicle control.

Discussion {#s0003}
==========

The degradation of proteins by autophagy and the ubiquitin-proteasome system is essential for mammalian development and homeostasis \[[@cit0069]\]. Consequently, a tight regulation of these degradation processes has to be ensured. For this reason, cells have developed a compensatory safety concept. If one degradation system is downregulated, the other gets upregulated to prevent cell-damaging protein overload\[[@cit0033],[@cit0034]\]. Thus, the regulation of both degradation systems in the same direction is rather uncommon. Our current study in combination with our previous report reveals that RPGRIP1L deficiency results in a decrease of proteasomal activity at the ciliary base and also in a reduction of autophagic activity demonstrating that RPGRIP1L positively controls both activities \[[@cit0028]\]. In this regard, the differentiation between autophagic and proteasomal activity was a difficult task.

Most proteins that are affected by one of these degradation systems are also associated with the other. In our current study, all analyzed proteins (MAP1LC3B, OFD1, BBS4) except ATG5 are related to both degradation processes: MAP1LC3 is not only a substrate of autophagy but also of the 20S proteasome \[[@cit0077]\]. Interestingly, the amount of MAP1LC3B-II in *rpgrip1l*^−/−^ MEFs was subject to the period of time in which these MEFs were serum starved. In *Rpgrip1l*-negative MEFs that were exposed to serum starvation for 6 h, the amount of MAP1LC3B-II was increased, whereas the amount of MAP1LC3B-II was reduced in *Rpgrip1l*-deficient MEFs that underwent serum starvation for 24 h ([Figure 1C](#f0001){ref-type="fig"}-E). In summary, these data suggest that the amount of MAP1LC3 is unaffected by the reduced proteasomal activity at the ciliary base caused by RPGRIP1L deficiency.

Potentially, MAP1LC3 is not degraded by the cilia-regulated proteasome but by other kinds of proteasomes. Remarkably, despite the opposing amounts of MAP1LC3B-II in *Rpgrip1l*-negative MEFs after serum starvation for 6 h and for 24 h ([Figure 1C](#f0001){ref-type="fig"} and Figure S1B), autophagy was decreased in the absence of RPGRIP1L under both conditions ([Figure 1D](#f0001){ref-type="fig"} and E). An explanation for this phenomenon could be that loss of RPGRIP1L hypothetically affects autophagy in 2 different ways: *rpgrip1l*^−/−^ MEFs that were serum starved for 6 h do not form cilia at all, while 10.4% of the wild-type MEFs possess cilia (Figure S1A). Previously, it was already speculated that primary cilia could be associated with autophagosome-lysosome fusion \[[@cit0078]\]. Consequently, the absence of RPGRIP1L may result in a blockade of later steps in the autophagy process, e.g. a perturbed fusion between autophagosomes and lysosomes leading to a smaller number of autolysosomes. Considering the accumulation of MAP1LC3B-II in the nucleus of *Rpgrip1l*-negative MEFs that underwent serum starvation for 6 h, it is likely that the production of MAP1LC3B-II and presumably also of autophagosomes is unaffected by RPGRIP1L deficiency.

It is also known from other studies that the amount of MAP1LC3B-II increases in case of an impaired autophagosome-lysosome fusion \[[@cit0079]\]. In the condition in which MEFs were serum starved for 24 h, a plethora of cilia was formed (Figure S1A) and loss of RPGRIP1L may disturb the generation of autophagosomes most likely by upregulating cilia-mediated MTOR signaling. Potentially, a residual autophagic activity and/or the cilia-independent proteasome degrades the high amount of MAP1LC3B-II and hence the high number of autophagosomes that was detected in *rpgrip1l*^−/−^ MEFs that were serum starved for 6 h. Because no new autophagosomes were formed, the amount of MAP1LC3B-II was decreased in *rpgrip1l*^−/−^ MEFs that were exposed to serum starvation for 24 h ([Figure 1C](#f0001){ref-type="fig"}). In summary, we propose that RPGRIP1L regulates the initiation of autophagy via governing MTOR signaling and later steps of autophagy (for example the fusion of autophagosomes and lysosomes) by a yet unknown mechanism. Future investigations should be undertaken to prove our two-way hypothesis.

In line with the finding that the absence of RPGRIP1L leads to a reduced autophagic activity, the autophagic substrate OFD1 is elevated by RPGRIP1L deficiency. It was previously reported that OFD1 positively regulates proteasomal activity. In contrast to RPGRIP1L, OFD1 controls the overall cellular proteasomal activity by controlling the amount of proteasomal components \[[@cit0063]\]. Although the loss of RPGRIP1L results in an increased amount of OFD1 at the ciliary base ([Figure 1F](#f0001){ref-type="fig"} and Figure S2B), overall cellular proteasomal activity is not altered and the proteasomal activity at the base of primary cilia is decreased \[[@cit0028]\]. In this context, it is remarkable that RPGRIP1L deficiency results in a reduced amount of BBS4 at the ciliary base ([Figure 1G](#f0001){ref-type="fig"} and Figure S2C), and that a positive regulation of overall proteasomal activity by BBS4 was formerly reported, raising the question of why the increased OFD1 amount or the decreased BBS4 amount at the ciliary base of *rpgrip1l*^−/−^ MEFs and limbs does not lead to an affected overall cellular proteasomal activity. Addressing this question in the future will make an important contribution to the understanding of the crosstalk between autophagy and the ubiquitin-proteasome system, which at least partly is mediated by ciliary proteins.

RPGRIP1L is not the only protein that regulates both autophagic and proteasomal activity in the same direction. Another protein that is involved in the regulation of both degradation processes in the same direction is USP14 (ubiquitin specific peptidase 14). This protein negatively controls proteasomal activity by trimming K48 ubiquitin chains on proteasome-bound substrates \[[@cit0083]\], and autophagic activity by governing K63 ubiquitination of BECN1/Beclin 1 \[[@cit0086]\]. Furthermore, the transcription factor FOXO3 (forkhead box O3) activates proteasomal proteolysis and autophagy. However, it performs this function exclusively in myotubes\[[@cit0087],[@cit0088]\]. Another factor that seems to control both degradation systems in a cell type-specific manner is the COP9 (Constitutive photomorphogenesis 9) complex consisting of the GPS1/CSN1/COPS1/COP9 signalosome 1 to COPS8/CSN8/COP9 signalosome 8 proteins. Su and colleagues showed that a conditional loss of the COPS8/CSN8 protein in murine hearts reduces the activity of the ubiquitin-proteasome system and the autophagic flux at the same time \[[@cit0089]\].

Interestingly, some of the GPS1-COPS proteins localize at the centrosome in HeLa cells \[[@cit0090]\]. Because the ciliary BB is built up by the centrosome, a localization of the GPS1-COPS complex at the cilium is conceivable. It is an interesting topic of future studies to test whether there is a relationship between GPS1-COPS proteins and RPGRIP1L. Moreover, it was reported that MTORC1 signaling does not only negatively control autophagic activity but also negatively regulates proteasomal activity \[[@cit0091]\]. However, another report described the opposite, namely that MTORC1 signaling positively governs proteasomal activity \[[@cit0092]\] leading to a controversial debate\[[@cit0093],[@cit0094]\]. Our current study revealed that RPGRIP1L deficiency results in elevated MTORC1 signaling ([Figure 2A](#f0002){ref-type="fig"} and [C](#f0002){ref-type="fig"}, [Figure 3G](#f0003){ref-type="fig"}) and our previous study showed that overall proteasomal activity is unaltered in *rpgrip1l*^−/−^ MEFs \[[@cit0028]\]. In combination, these data indicate that the increased MTORC1 signaling does not affect overall proteasomal activity at all in the absence of RPGRIP1L. Furthermore, the investigations in which we used the MTORC1 inhibitor rapamycin uncovered that proteasomal activity at the ciliary base is not regulated by MTORC1 signaling (Figure S5C).

Previously, we showed that RPGRIP1L governs proteasomal activity at the ciliary base via interacting with the PSMD2 (proteasome \[prosome, macropain\] 26S subunit, non-ATPase, 2) protein, a component of the regulatory proteasomal 19S subunit. In doing so, RPGRIP1L controls cilia-mediated SHH signaling \[[@cit0028]\]. Although SHH signaling governs autophagy in MEFs, RPGRIP1L does not regulate autophagy via SHH signaling ([Figure 3I](#f0003){ref-type="fig"} and [J](#f0003){ref-type="fig"}). In MEFs, the regulation of autophagy by RPGRIP1L is accomplished via MTORC1 signaling ([Figure 2A](#f0002){ref-type="fig"} and [D](#f0002){ref-type="fig"}). Interestingly, several studies reported the localization of AKT1, a protein acting upstream of MTOR, to primary cilia: For example, the activated form of AKT1 is localized at the basal body of cilia in murine 3T3-L1 preadipocytes and in cortical progenitors\[[@cit0057],[@cit0095]\]. In addition, it was shown that activated AKT1 colocalizes with HSP90 (heat shock protein 90) at the ciliary base making this part of the cilium a possible candidate for the activation of AKT1 signaling \[[@cit0058]\]. Our data reveal that the amount of phospho-(Ser473)-AKT1 and phospho-(Ser2448)-MTOR is elevated in *Rpgrip1l*-deficient MEFs ([Figure 2A](#f0002){ref-type="fig"} and [Figure 3C](#f0003){ref-type="fig"}). Remarkably, we did not only detect the increased amount of these 2 proteins in whole cell lysates but also at primary cilia ([Figure 3E](#f0003){ref-type="fig"} and [G](#f0003){ref-type="fig"}) demonstrating that more activated AKT1 and MTOR protein is present at *Rpgrip1l*-negative MEF cilia. These data together with the fact that the treatment of *rpgrip1l*^−/−^ MEFs with the MTOR inhibitor rapamycin leads to a rescue of autophagic activity indicate that RPGRIP1L controls the phosphorylation of MTOR and hence autophagy by governing the activation of AKT1. The mechanism by which RPGRIP1L realizes the regulation of AKT1 phosphorylation remains to be elucidated in the future.

By using different pharmacological activators and inhibitors of autophagy and the proteasome, we suggest that RPGRIP1L regulates the 2 protein degradation processes independently from each other. It is a difficult endeavor to discriminate between autophagic and proteasomal activity because many drugs that have an effect on the one degradation system often also affect the other. The drugs used in the current study include rapamycin, SFN, 18α-GA, ABT-737 and 3-MA. Rapamycin is one of the best studied autophagy activators but it was reported that it is also able to affect proteasomal activity\[[@cit0051],[@cit0096],[@cit0097]\]. An inhibition of proteasomal activity by rapamycin was shown in lymphocytes \[[@cit0097]\], MEFs and human embryonic kidney (HEK293) cells \[[@cit0092]\], whereas a rapamycin-induced activation of proteasomal activity was reported in MEFs, HEK293 cells and the murine liver \[[@cit0091]\]. SFN and 18α-GA are well-known proteasome activators but can also activate autophagy. In the case of SFN, this autophagy-activating function was shown in pancreatic cancer cells \[[@cit0098]\], human prostate cancer cell line (PC-3) \[[@cit0099]\], human androgen-dependent prostate cancer cells, human neuroblastoma cells \[[@cit0100]\], immortalized human hepatocytes \[[@cit0101]\], murine neurons \[[@cit0102]\] and the mouse brain \[[@cit0103]\]. 18α-GA serves as a proteasome activator in human embryonic fibroblasts \[[@cit0062]\], in human bone marrow stromal cells \[[@cit0104]\] and in human as well as murine neuronal cells \[[@cit0105]\] and functions as an autophagy activator in hepatocellular carcinoma cells \[[@cit0106]\] and in non-small cell lung cancer cells \[[@cit0107]\]. Thus, an effect on both autophagic and proteasomal activity, was reported for all three drugs. However, in MEFs, we did neither detect any effect of rapamycin on the proteasomal activity at the ciliary base (Figure S5C) nor any impact of SFN or 18α-GA on autophagic activity (Figure S3, Figure S4). Accordingly, the treatment of wild-type and *rpgrip1l*^−/−^ MEFs with rapamycin, SFN or 18α-GA allows us to differentiate between autophagic and proteasomal activity at the ciliary base.

ABT-737 activates autophagy \[[@cit0064]\], whereas 3-MA is an autophagy inhibitor \[[@cit0065]\]. Until now, no connection between ABT-737 or 3-MA and the proteasome was reported. We analyzed the processing of GLI3, which is realized specifically by the cilia-regulated proteasome (see [@cit0035] and [@cit0071]), in wild-type and *rpgrip1l*^−/−^ MEFs after treatment with ABT-737 or 3-MA and found no alteration (Figure S5A and S5B). Thus, the activation or the inhibition of autophagy does not affect proteasomal activity at the ciliary base in MEFs. Together, the results of the drug treatments in MEFs strongly argue for a scenario in which RPGRIP1L regulates proteasomal activity at the ciliary base and autophagy independently of each other. However, because all of our treatments have been carried out in vitro, we cannot conclude that the drugs used in our study exert the same effects in vivo.

Remarkably, on the one hand, ciliary proteins have an impact on autophagy, and, on the other hand, autophagy has an effect on cilia. In this context, several studies revealed that autophagy is able to regulate cilia length \[[@cit0108]\]. Our investigations showed that the reduced autophagic activity in the absence of RPGRIP1L leads to an elongation of cilia ([Figure 4](#f0004){ref-type="fig"}). Treatment of MEFs with the autophagy activators rapamycin (affects autophagy by inhibiting MTOR) and ABT-737 (affects autophagy but not protein synthesis) reduces cilia length ([Figure 4A](#f0004){ref-type="fig"} and [C](#f0004){ref-type="fig"}) demonstrating that autophagy is able to modulate cilia length in MEFs independently of MTOR-regulated protein synthesis. Interestingly, a study in the zebrafish also reported that the usage of rapamycin reduces ciliary length \[[@cit0067]\]. Noticeably, our treatment with the autophagy inhibitor 3-MA increases the length of cilia in wild-type MEFs but does not elongate cilia in *rpgrip1l*^−/−^ MEFs ([Figure 4B](#f0004){ref-type="fig"}). We assume that RPGRIP1L deficiency decreases autophagic activity to such a low level that 3-MA has no impact on autophagy-regulated cilia length in these cells.

In contrast to our findings, Wang et al. showed that inhibition of autophagy via 3-MA leads to a decreased cilia length in HK2 cells \[[@cit0111]\]. As this cell line is derived from human kidney cells, we hypothesize a cell type-dependent role of autophagy in the regulation of ciliary length. In the same study, it was demonstrated that ciliary length is affected by a cooperative activity of the proteasome and autophagy in HK2 cells \[[@cit0111]\]. We found another situation in MEFs. Combined with the data of our previous report in which the proteasome activator SFN was not able to restore cilia length in *Rpgrip1l*-negative MEFs, we conclude that RPGRIP1L controls cilia length via regulating autophagy but not by governing proteasomal activity at the ciliary base \[[@cit0028]\]. In summary, we propose that the differences that exist between the findings of our study and the results of other reports are caused by the analysis of different cell types.

One of the most important questions raised by our findings is whether reduced autophagic activity takes part in the development of human ciliopathies caused by mutations in *RPGRIP1L*. Previously, it was reported that autophagy plays an important role in vertebrate development\[[@cit0070],[@cit0071],[@cit0112]\]. Autophagy is involved in the embryonic development of the brain \[[@cit0115]\], the eyes \[[@cit0116]\], the lung \[[@cit0119]\], the heart\[[@cit0120],[@cit0121]\] and the liver \[[@cit0120]\]. To evaluate the importance of our findings for human health, it would be an interesting future task to analyze autophagic activity in ciliopathy patients who carry a mutation in *RPGRIP1L*. Previously, it was shown that prenatal rapamycin treatment reduced cystogenesis in *pkd1^−/−^* mice, a well-established mammalian model for polycystic kidney disease, a medical condition that is associated with dysfunctional cilia \[[@cit0122]\]. However, this positive effect was not linked to autophagy but was only related to the relationship of upregulated MTOR signaling and cyst formation. So far, it is unknown if treatment with rapamycin has also positive impacts on other ciliopathy symptoms. Treatment of *rpgrip1l^−/−^* mouse embryos with rapamycin would shed light on this open question. Accordingly, the decreased autophagic activity and the impaired proteasomal activity could be 2 independent reasons for the development of ciliopathy symptoms in *Rpgrip1l*-negative mouse embryos. On that account, the rescue of both activities together could be the decisive step to treat, heal or even prevent ciliopathies caused by mutations in *RPGRIP1L*.

Materials and methods {#s0004}
=====================

Ethics statement and animal husbandry {#s0004-0001}
-------------------------------------

All mice (*Mus musculus*) used in this study were on the C3H background and kept under standard housing conditions (12/12-h dark-light cycle; with food and water ad libitum). Animal procedures were performed in accordance with National Institutes of Health guidelines and with local and state regulations for research with animals.

Mouse strains {#s0004-0002}
-------------

We mated *Rpgrip1l^+/−^* male and female mice to obtain wild-type and *rpgrip1l^−/−^* mouse embryos. *Rpgrip1l*-heterozygous mutant mice were generated as described previously \[[@cit0029]\].

Primary antibodies {#s0004-0003}
------------------

In this study, the following primary antibodies were used: rabbit anti-ACT (Sigma-Aldrich, A2066), mouse anti-GAPDH (Sigma-Aldrich, G8795), goat anti-GLI3 (R&D systems, AF3690), rabbit anti-phospho-(Ser2448)-MTOR (Cell Signaling Technology, 2971), rabbit anti-TSC1 (Cell Signaling Technology, 4906), rabbit anti-phospho-(Ser939)-TSC2 (Cell Signaling Technology, 3615), rabbit anti-phospho-(Ser473)-AKT1 (Cell Signaling Technology, 9271), mouse anti-Ac-TUBA (Santa Cruz Biotechnology, sc-23950), goat anti-TUBG (Santa Cruz Biotechnology, sc-7396), rabbit anti-BBS4 (Proteintech Group Inc., 12766-1-AP), rabbit anti-MAP1LC3B (Cell Signaling Technology, 2775), rabbit anti-MAP1LC3B (Abcam, ab48394), rabbit anti-OFD1 (kind gift provided by Brunella Franco; TIGEM, Italy), rabbit anti-MTOR (Cell Signaling Technology, 2983), rabbit anti-AKT1 (Cell Signaling Technology, 4691), rabbit anti-TSC2 (Abcam, ab32554), mouse anti-GFP (Roche, 11814460001), rabbit anti-phospho-(Ser33/37/Thr41)-CTNNB1 (Cell Signaling Technology, 9561), mouse anti-ATG5 (Proteintech Group Inc., 60061-1-LG), rabbit anti-ubiquitin (Sigma-Aldrich, U5379).

Autophagic flux assay {#s0004-0004}
---------------------

For the autophagic flux assay MEFs were treated for 6 h with 40 μM chloroquine (Sigma-Aldrich, C6628) dissolved in DMEM containing no serum. Alternatively, MEFs were serum starved for 24 h with an additional CQ treatment within the last 6 h. Serum-deprived MEFs served as control. Cells were harvested in radioimmunoprecipitation buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 0.1% sodium deoxycholate (Sigma-Aldrich, D6750), 1 mM EDTA) and prepared for western blot analysis. Calculation of the autophagic flux was performed via subtracting the quantified and normalized (to the ACT loading control) MAP1LC3B amount (in procedure defined units) of the CQ-treated MEFs from the quantified and normalized MAP1LC3B amount of the untreated MEFs.

Cell culture, transfection, and drug treatment {#s0004-0005}
----------------------------------------------

For MEF isolation, single embryos (E12.5) were used. MEFs were grown in DMEM supplemented with 10% fetal calf serum, 1:100 (vol:vol) L-glutamine (Gibco, 25030-024), 1:100 (vol:vol) sodium pyruvate (Gibco, 11360-39), 1:100 (vol:vol) nonessential amino acids (Gibco, 1140-35), and 1:100 (vol:vol) penicillin/streptomycin (Gibco, 15140-122) at 37°C and 5% CO~2~. Ciliogenesis was induced by starving confluent MEFs in medium containing 0.5% fetal calf serum for at least 24 h.

GLI1 overexpression in MEFs was achieved via transfection of a construct encoding a HsGLI1-EGFP fusion protein. Full-length HsGLI1 was cloned into a p-EGFP-C1 vector (BD Biosciences Clontech, 6084-1). Transfection was performed using the Lipofectamine 3000 detergent (Thermo Fisher Scientific, L3000008) when the MEFs reached 70--80% confluency. At 6--10 h after transfection, MEFs were serum starved for 24 h. Cells were either harvested for western blot analysis or fixed and stained for fluorescence microscopy.

Cells were treated for 20 h with 10 nM rapamycin (Cell Signaling Technology, 9904), for 20 h with 10 µM 3-methyladenine (Sigma-Aldrich, M9281), 5 µM SFN (Enzo Life Sciences, ALX-350-230-M010), for 6 h with 1 µM ABT-737 (Viva Bioscience, B2766-0001), for 2 h with 2 µg/ml 18α-GA (Sigma-Aldrich, G8503-250MG) or 6 h with 40 µM CQ (Sigma-Aldrich, C-6628). As a solvent control, cells were treated for the same time with 0.1% DMSO; in the case of 3-methyladenine, 18α-GA and CQ, serum-deprived DMEM served as solvent and thereby as control. To stimulate SHH signaling, cells were treated for 24 h with 200 nM SAG (Calbiochem, 566660). All treatment experiments were repeated 3 independent times.

Cryosections {#s0004-0006}
------------

The isolated embryos were fixed in 4% paraformaldehyde for 2 h at room temperature. Subsequently, the limbs were separated from the animals and incubated separately in 30% sucrose (Merck, 107651; in PBS \[4 mM NaH~2~PO~4~·H~2~O, 16 mM Na~2~HPO~4~·2H~2~O, 150 mM NaCl\]) over night (o/n) at 4°C. On the following day, embryos and limbs were embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek Inc., 4583) and then stored at -80°C. Transverse cryostat sections (7 µm in thickness) were prepared. For staining with anti-OFD1, the sections were fixed 10 min in MeOH at -20°C.

Immunofluorescence {#s0004-0007}
------------------

For immunofluorescence of MEFs, cells were grown on coverslips until confluency. After serum starvation for 24 h, MEFs were fixed with 4% paraformaldehyde (for stainings with the antibodies to phospho-\[Ser473\]-AKT1, Ac-TUBA, phospho-\[Ser33/37/Thr41\]-CTNNB1 and phospho-\[Ser2448\]-MTOR) or methanol (for stainings with the antibodies against BBS4, MAP1LC3B, CDH, ubiquitin, ATG5 and OFD1). Fixed cells were rinsed 3 times with sterile PBS. Permeabilization was performed by incubating the cells in PBS-0.5% Triton X-100 (AppliChem, A4975,0500) for 10 min. After 3 washes with PBS-0.1% Triton X-100, unspecific antigens were blocked for at least 1 h at room temperature using PBS-0.1% Triton X-100 containing 10% donkey serum (EMD Millipore, S30-100ML). In blocking solution, diluted primary antibodies were incubated o/n at 4°C. After 3 washing steps with PBS-0.1% Triton X-100, incubation with fluorescent secondary antibody (Jackson ImmunoResearch Laboratories) all were raised in donkeys, anti-mouse Alexa 488 (711-545-151), anti-rabbit Alexa 488 (711-545-152), anti-mouse Cy 3 (715-165-151), anti-rabbit Cy 3 (715-165-152), anti-rabbit Dylight 405 (711-475-152), anti-goat Dylight 405 (705-475-003) diluted in block was performed at room temperature for 1 h followed by several washings and subsequent embedding with Mowiol (Sigma-Aldrich, 81381).

For immunofluorescence on limb cryosections, sections were permeabilized with PBS-0.5% Triton X-100 for 15 min at room temperature. Blocking was performed with 10% donkey serum in PBS-0.1% Triton X-100. The sections then were incubated with the primary antibodies diluted in block o/n at 4°C. After 3 washing steps, sections were incubated in the secondary antibody (again diluted in blocking solution) for 2 h at 37°C and then washed again. Finally, they were embedded in Mowiol.

Image processing {#s0004-0008}
----------------

Image acquisition and data analysis were performed at room temperature using a microscope (Imager.A2; Carl Zeiss), 100x, NA 1.46 oil immersion objective lens (Carl Zeiss), a monochrome charge-coupled device camera (AxioCam MRm; Carl Zeiss), and the AxioVision Rel. 4.8 software package (Carl Zeiss).

3D-structured illumination microscopy (3D-SIM) was performed on a Zeiss ELYRA PS.1 system (Carl Zeiss) equipped with an Andor EM-CCD iXON DU-885 with 1004 × 1002 pixels at room temperature. Z-stacks were taken using a 100x alpha-Plan-Apochromat oil immersion objective with a numerical aperture of 1.46. To generate structured illumination a grid pattern is projected onto the image plane in 5 different positions and at 5 different modulation angles to obtain high frequency information within the low frequency information captured by the optical system. For the Dylight405-, Dylight488-, Cy3-channel back-computation of the lower frequencies using Fourier transformation was performed using the Zeiss ZEN Structured Illumination Processing tool to increase the resolution in the final image.

Appropriate anti-mouse, rabbit, or goat Cy3, Dylight405 or Dylight488 fluorochrome--conjugated secondary antibodies (Jackson ImmunoResearch, 711-165-152; Jackson ImmunoResearch, 705-475-003; Jackson ImmunoResearch, 715-485-151) were used to detect primary antibody binding. The following Phalloidin-conjugates were used: CytoPainter Phalloidin-iFluor 488 reagent (Abcam, ab176753); CytoPainter Phalloidin-iFluor 405 reagent (Abcam, ab176752) and TRITC-Phalloidin (Sigma-Aldrich, P1951).

Quantifications of immunofluorescence intensities {#s0004-0009}
-------------------------------------------------

Intensity of ciliary protein staining was quantified using ImageJ (National Institutes of Health). For the measurement of fluorescence intensities of ciliary base proteins, we selected the region labeled by TUBG and the area in-between the TUBG staining and the proximal part of the Ac-TUBA staining and measured the total pixel intensity. For quantifications of the fluorescence intensity of the phospho-(Ser473)-AKT1 signal, we used the area marked by Ac-TUBA and quantified the average pixel intensity to take the cilia length into account, thereby making the data of wild-type and *rpgrip1l^−/−^* cilia comparable. To get rid of the ratio of nonspecific (background) staining, we subtracted the mean value of the average pixel intensity (in the case of phospho-\[Ser473\]-AKT1) or of the total pixel intensity (for all ciliary base proteins) of 3 neighboring regions free from specific staining.

Quantifications of autophagosomes in MEFs {#s0004-0010}
-----------------------------------------

All measurements (either MAP1LC3B or ATG5) were performed in Fiji (National Institues of Health). Images were loaded into the software and single-color planes were merged. The cell border was marked and the total cell area was measured. The red channel within this area was copied and pasted into a new Fiji file. Total autophagosome area was measured via the "Object counter" Plugin, whereas an intensity threshold between 30 and 40 (for both wild-type and *Rpgrip1l*-deficient MEFs) was used to automatically mark the autophagosomes and thereby measure their area. All autophagosome areas for one cell were summed up. A ratio between their sum and the total cell area was calculated. For each individual per genotype, at least 10 cells and their autophagosomes were measured.

Quantitative real-time reverse transcriptase PCR analysis {#s0004-0011}
---------------------------------------------------------

All quantitative real-time reverse transcriptase PCR analysis were performed using TaqMan™ probes and a StepOne™ Real-Time PCR System (Thermo Fisher Scientific/Applied Biosystems). The used TaqMan™ probes were *Ptch1* (Thermo Fisher Scientific/Applied Biosystems, Mm00436026_m1) and *Gapdh* (Thermo Fisher Scientific/Applied Biosystems, Mm99999915_g1) as a housekeeping gene. Measurements were performed in triplets. Expression differences between wild-type and *Rpgrip1l*-deficient MEFs were calculated via the ΔΔCt-method.

Semiquantitative PCR analysis {#s0004-0012}
-----------------------------

MEF total cell RNA was isolated using the RNeasy Mini Kit (Qiagen, 74104) and a RNase-Free DNase Set (Qiagen, 79254). The RNA was transcribed into cDNA by usage of a reverse transcriptase system (Roche, 11785826001). With this cDNA a semiquantitative PCR for *Hif1a* was performed, while *Hprt* was used for normalization. The following primers were used: *Hif1a* forw.: TGATGCTCTCACTCTGCTGG*Hif1a* rev.: AGAAGGACTTGCTGGCTGAT*Hprt* forw.: CACAGGACTAGAACACCTGC*Hprt* rev.: GCTGGTGAAAAGGACCTCT

Western blotting {#s0005}
================

Whole-cell lysates were obtained by lysis with radioimmunoprecipitation buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 0.1% sodium deoxycholate, 1 mM EDTA). The Bradford method was used to determine the protein amount. All samples were normalized. Total protein (20 μg) was separated by SDS-PAGE on polyacrylamide gels (10% or 15%) and transferred to a PVDF membrane (Bio-Rad Laboratories Inc., 1620177). Blocking was performed in either skimmed milk powder or bovine serum albumin dissolved in PBS-0.1% Tween 20 (Carl Roth GmbH + Co. KG, 9127.1) or TBS (20 mM NaCl, 150 mM Tris)-0.1% Tween 20. The membrane was incubated with antibodies against MAP1LC3B (in this case the antibody from Cell Signaling Technology was used), GLI3, phospho-(Ser2448)-MTOR, non-phospho-MTOR, TSC1, phospho-(Ser939)-TSC2, non-phospho-TSC2, phospho-(Ser473)-AKT1, non-phospho-AKT1, GLI1 or GFP. Anti-ACT antibody was used as loading control. Proteins were detected with secondary antibodies conjugated to horseradish peroxidase (DakoCytomation, P0260; DakoCytomation, P0448; Santa Cruz Biotechnology, sc-2020) and the ECL detection kit (GE Healthcare, RPN2232). Band visualization was performed using a LAS-4000 mini (Fujifilm) and their intensities were measured using the Fiji Software (National Institutes of Health).

Figure preparation {#s0006}
==================

Figure preparation was performed by using Photoshop 7 or CS4 (Adobe), and collages of all images for figure preparation were arranged using Illustrator CS4 (Adobe).

Statistical data {#s0007}
================

Data are presented as means ± SEM. A 2-tailed Student *t* test was performed for all compared data by using Excel (Microsoft). A P \< 0.05 was considered to be statistically significant (\*), a P \< 0.01 was regarded as statistically very significant (\*\*), and a P \< 0.001 was considered to be highly significant statistically (\*\*\*).
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